New Ways to Treat Triple Negative Breast Cancer
Integrating Low-Cost Paper-Based Devices and Personalized Immunotherapeutics to Treat Triple Negative Breast Cancer
This project aims to develop new, personalized treatments for triple negative breast cancer, especially for minority populations, using affordable paper-based tools.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Delaware State University NIH-funded |
| Lab location | 1 site (Dover, United States) |
| Project ID | NIH-11095734 on NIH RePORTER |
What this research studies
When breast cancer is diagnosed as "triple negative," it means common targeted therapies don't work because the cancer cells lack specific receptors. This leaves patients with more toxic chemotherapy options and often requires drastic surgeries. Our goal is to create personalized immune-boosting treatments that are more effective and less harmful. We are also developing low-cost paper-based devices to help guide these treatments, making them more accessible. This work focuses on improving outcomes for those with this aggressive form of breast cancer, particularly within minority communities who are disproportionately affected.
Who could benefit from this research
Good fit: Patients diagnosed with triple negative breast cancer, particularly those from minority populations, would be the primary beneficiaries of this research.
Not a fit: Patients with other types of breast cancer (ER+, PR+, or HER2+) who already have targeted therapies available would not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to more effective, less toxic, and personalized treatment options for patients with triple negative breast cancer.
How similar studies have performed: While personalized immunotherapies are a growing field, this specific integration with low-cost paper-based devices for TNBC represents a novel and promising approach.
Where this research is happening
Dover, United States
- Delaware State University — Dover, United States (Active)
Researchers
- Principal investigator: Islam, M Shahidul — Delaware State University
- Study coordinator: Islam, M Shahidul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.